Update on the biology and therapy of gastrointestinal stromal tumors

Gina D'Amato, Dejka M. Steinert, John C. McAuliffe, Jonathan C. Trent

Research output: Contribution to journalReview article

102 Citations (Scopus)

Abstract

Background: Gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumors of the gastrointestinal tract, are an example of a disease with an effective, molecularly targeted therapy. Methods: Published articles and author experience were used to comprehensively define the clinical features, biology, and state-of-the-art therapy of GISTs. Results: GISTs are thought to originate from the neoplastic transformation of the interstitial cells of Cajal, the intestinal pacemaker cells. GISTs commonly have mutations in the kit gene, resulting in a gain-of-function mutation and ligand-independent constitutive activation of the KIT receptor tyrosine kinase. Successful tyrosine kinase inhibitors target the aberrant pathways that are critical for tumor cell viability. The development of imatinib mesylate (formerly STI571) in the treatment of metastatic GISTs represents a therapeutic breakthrough. Conclusions: Progress in the clinical diagnosis has led to an increased recognition of this disease as a distinct clinical entity. Treatment of metastatic GIST with imatinib has led to unprecedented improvements in progression-free and overall survival. The use of imatinib in the preoperative and postoperative treatment of GISTs is an area of intense investigation.

Original languageEnglish (US)
Pages (from-to)44-56
Number of pages13
JournalCancer Control
Volume12
Issue number1
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Therapeutics
Interstitial Cells of Cajal
Art Therapy
Mutation
Critical Pathways
Receptor Protein-Tyrosine Kinases
Protein-Tyrosine Kinases
Disease-Free Survival
Gastrointestinal Tract
Neoplasms
Cell Survival
Ligands
Imatinib Mesylate
Genes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

D'Amato, G., Steinert, D. M., McAuliffe, J. C., & Trent, J. C. (2005). Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control, 12(1), 44-56.

Update on the biology and therapy of gastrointestinal stromal tumors. / D'Amato, Gina; Steinert, Dejka M.; McAuliffe, John C.; Trent, Jonathan C.

In: Cancer Control, Vol. 12, No. 1, 01.2005, p. 44-56.

Research output: Contribution to journalReview article

D'Amato, G, Steinert, DM, McAuliffe, JC & Trent, JC 2005, 'Update on the biology and therapy of gastrointestinal stromal tumors', Cancer Control, vol. 12, no. 1, pp. 44-56.
D'Amato, Gina ; Steinert, Dejka M. ; McAuliffe, John C. ; Trent, Jonathan C. / Update on the biology and therapy of gastrointestinal stromal tumors. In: Cancer Control. 2005 ; Vol. 12, No. 1. pp. 44-56.
@article{9a6738f809c24b1d878cf383426f6212,
title = "Update on the biology and therapy of gastrointestinal stromal tumors",
abstract = "Background: Gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumors of the gastrointestinal tract, are an example of a disease with an effective, molecularly targeted therapy. Methods: Published articles and author experience were used to comprehensively define the clinical features, biology, and state-of-the-art therapy of GISTs. Results: GISTs are thought to originate from the neoplastic transformation of the interstitial cells of Cajal, the intestinal pacemaker cells. GISTs commonly have mutations in the kit gene, resulting in a gain-of-function mutation and ligand-independent constitutive activation of the KIT receptor tyrosine kinase. Successful tyrosine kinase inhibitors target the aberrant pathways that are critical for tumor cell viability. The development of imatinib mesylate (formerly STI571) in the treatment of metastatic GISTs represents a therapeutic breakthrough. Conclusions: Progress in the clinical diagnosis has led to an increased recognition of this disease as a distinct clinical entity. Treatment of metastatic GIST with imatinib has led to unprecedented improvements in progression-free and overall survival. The use of imatinib in the preoperative and postoperative treatment of GISTs is an area of intense investigation.",
author = "Gina D'Amato and Steinert, {Dejka M.} and McAuliffe, {John C.} and Trent, {Jonathan C.}",
year = "2005",
month = "1",
language = "English (US)",
volume = "12",
pages = "44--56",
journal = "Cancer control : journal of the Moffitt Cancer Center.",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "1",

}

TY - JOUR

T1 - Update on the biology and therapy of gastrointestinal stromal tumors

AU - D'Amato, Gina

AU - Steinert, Dejka M.

AU - McAuliffe, John C.

AU - Trent, Jonathan C.

PY - 2005/1

Y1 - 2005/1

N2 - Background: Gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumors of the gastrointestinal tract, are an example of a disease with an effective, molecularly targeted therapy. Methods: Published articles and author experience were used to comprehensively define the clinical features, biology, and state-of-the-art therapy of GISTs. Results: GISTs are thought to originate from the neoplastic transformation of the interstitial cells of Cajal, the intestinal pacemaker cells. GISTs commonly have mutations in the kit gene, resulting in a gain-of-function mutation and ligand-independent constitutive activation of the KIT receptor tyrosine kinase. Successful tyrosine kinase inhibitors target the aberrant pathways that are critical for tumor cell viability. The development of imatinib mesylate (formerly STI571) in the treatment of metastatic GISTs represents a therapeutic breakthrough. Conclusions: Progress in the clinical diagnosis has led to an increased recognition of this disease as a distinct clinical entity. Treatment of metastatic GIST with imatinib has led to unprecedented improvements in progression-free and overall survival. The use of imatinib in the preoperative and postoperative treatment of GISTs is an area of intense investigation.

AB - Background: Gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumors of the gastrointestinal tract, are an example of a disease with an effective, molecularly targeted therapy. Methods: Published articles and author experience were used to comprehensively define the clinical features, biology, and state-of-the-art therapy of GISTs. Results: GISTs are thought to originate from the neoplastic transformation of the interstitial cells of Cajal, the intestinal pacemaker cells. GISTs commonly have mutations in the kit gene, resulting in a gain-of-function mutation and ligand-independent constitutive activation of the KIT receptor tyrosine kinase. Successful tyrosine kinase inhibitors target the aberrant pathways that are critical for tumor cell viability. The development of imatinib mesylate (formerly STI571) in the treatment of metastatic GISTs represents a therapeutic breakthrough. Conclusions: Progress in the clinical diagnosis has led to an increased recognition of this disease as a distinct clinical entity. Treatment of metastatic GIST with imatinib has led to unprecedented improvements in progression-free and overall survival. The use of imatinib in the preoperative and postoperative treatment of GISTs is an area of intense investigation.

UR - http://www.scopus.com/inward/record.url?scp=12744274526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12744274526&partnerID=8YFLogxK

M3 - Review article

C2 - 15668652

AN - SCOPUS:12744274526

VL - 12

SP - 44

EP - 56

JO - Cancer control : journal of the Moffitt Cancer Center.

JF - Cancer control : journal of the Moffitt Cancer Center.

SN - 1073-2748

IS - 1

ER -